Peptides for Recovery and Performance: An Honest, Evidence-Based Guide

Peptides are one of the fastest-growing areas in recovery and longevity, used by many thousands of people, and one of the most misunderstood. Searches for compounds like follistatin, GHK-Cu, ipamorelin, MOTS-C and TB-500 have climbed sharply since 2024. This guide gives you the straight version: what each peptide is, how it actually works, what the science supports today, and where each one sits as the regulatory picture evolves.

The big picture first

A few things are true of most peptides used for recovery and performance, and holding them together is the key to a sensible view:

• Real mechanisms, early human data. Most have a genuine, plausible biological rationale and encouraging animal data. What is still catching up is rigorous human outcome research, so for many of them the honest label is promising rather than proven.
• The regulatory picture is moving. A few related compounds are already approved medicines. And in 2026 the FDA's Pharmacy Compounding Advisory Committee scheduled a hearing (23 to 24 July 2026) to review whether several popular peptides, including BPC-157, TB-500 and MOTS-C, should be eligible for legal pharmacy compounding. Regulators are reconsidering these, not dismissing them.
• Product quality is the practical risk. The biggest day-to-day danger for most people is not the molecule but the source: peptides made outside Good Manufacturing Practice can carry contamination, the wrong dose, or mislabeling. This is exactly what proper sourcing and medical supervision address.

For completeness on the sporting side, most of these peptides are on the World Anti-Doping Agency list, which is relevant only if you compete in a tested sport.

Approved medicines (used for specific conditions)

These are genuine, regulator-approved peptide medicines. That does not make them performance drugs, and the recovery and athletic claims attached to them are largely unproven, but they sit in a very different category from grey-market compounds.

• Sermorelin and Tesamorelin (Egrifta) are growth-hormone-releasing hormone (GHRH) analogs. Tesamorelin is approved to reduce visceral fat in a specific patient group; both are promoted off-label for body composition and connective-tissue healing, where the evidence is far weaker. Read our detailed review: Sermorelin and Tesamorelin explained.
• SS-31 (elamipretide) is a mitochondrial peptide recently approved under accelerated approval for a rare metabolic disease. In healthy people, a single infusion improved muscle mitochondrial energy production but did not reduce muscle fatigue, so its performance value is unproven. It is one of the few not on the WADA list.

Unapproved, grey-market peptides

These are the compounds most people mean when they talk about "peptides." Each has a real, specific mechanism and encouraging early data. The honest common thread is that human outcome research is still developing, and that buying them unregulated is the main practical risk, which is why medical oversight matters most here.

• BPC-157. A gastric peptide that acts on real repair pathways such as angiogenesis, with strong, consistent animal data and an encouraging early human signal. Now under FDA review for legal compounding. Full review: BPC-157 for injury recovery.
• TB-500 / thymosin beta-4. A fragment of a natural wound-healing protein that drives cell migration and new blood vessels. Encouraging mechanism, early human data, and one specific safety point (a cancer-association signal) that makes oversight worthwhile. Full review: TB-500 and thymosin beta-4.
• GHK-Cu. A copper peptide genuinely approved for topical cosmetic use, where it stimulates collagen and skin repair. The injectable version is less proven and needs care over copper. Full review: GHK-Cu copper peptide.
• CJC-1295 and Ipamorelin. Two growth-hormone-stimulating peptides, almost always used together, that reliably raise growth hormone and IGF-1. Human outcome data are still limited, and they warrant monitoring of glucose and the pituitary. Full review: CJC-1295 and ipamorelin.
• MOTS-C. A mitochondrial-derived peptide that activates AMPK and acts as an exercise mimetic. Interesting biology, early human data, and now under FDA review for legal compounding. Full review: MOTS-C.
• Follistatin (FS-344). A myostatin blocker that produces dramatic muscle growth in animal gene-therapy studies; the injected peptide people buy is a different, less-tested route. Full review: Follistatin (FS-344).
• AOD-9604. A growth-hormone fragment marketed for fat loss. It went through six randomized human trials for obesity and, despite a reassuring safety profile, did not show meaningful efficacy.

Where regulation is heading

The headline is that the picture is opening up rather than closing down. Several of these peptides are being formally reconsidered by the FDA in 2026 for legal pharmacy compounding, which would give patients a regulated, quality-controlled route instead of the grey market. Until that happens, the key point is simply that an unapproved compound has no regulator vouching for its quality or dose, which is the strongest argument for using these only with medical guidance.

The foundations still come first

Whatever you decide about peptides, the basics do the heavy lifting and are worth getting right first: an accurate diagnosis of what is actually wrong, structured rehabilitation, sensible load management, sleep, and nutrition with adequate protein. For specific musculoskeletal problems, established options such as physiotherapy, and in selected cases regenerative treatments, are well supported. Peptides, where appropriate, sit on top of these foundations rather than replacing them.

Our take

We are genuinely interested in this science. The mechanisms are real, the early data are encouraging, large numbers of people already use these compounds, and regulators are now reviewing several of them. Our role is not to hype them or to wave them away, but to give you a straight, individualized read: what the evidence supports, what the risks are, and how to reduce them.

In practice that means if you are considering peptides, or already using them, the safest path is to do it under medical supervision, with proper assessment, attention to product quality, and monitoring, on top of the recovery fundamentals. Neither hype nor a flat no.